Article List

WPRIM Management System> DCMS> Chinese Journal of Cardiology> 2013> 41> 3

Volume: 41 Issue: 3

1. Progresses in injectable myocardial tissue engineering.	Page:262—264
2. Associations of blood pressure level with carotid intima-media thickness and plaque among middle-aged and elderly Chinese hypertensives.	Page:256—259
3. Control rate of increased low-density lipoprotein cholesterol levels in cardiology outpatients with coronary heart disease in Beijing.	Page:251—255
4. Effects of noncoding RNA NRON gene regulation on human umbilical vein endothelial cells functions.	Page:245—250
5. Fasudil reverses monocrotaline-induced pulmonary hypertension in rats.	Page:239—244
6. Efficacy of catheter radiofrequency ablation for the treatment of ventricular arrhythmia storm post cardioverter-defibrillators implantation.	Page:233—238
7. Retrospective analysis of patients with thrombocytopenia after patent ductus arteriosus interventional occlusion.	Page:229—232
8. Chronic effects of 100 mg/2 hours recombinant tissue-type plasminogen activator therapy regimen for patients with acute pulmonary thromboembolism.	Page:224—228
9. Impact of systolic blood pressure on visit-to-visit blood pressure variability in middle-aged and elderly people.	Page:219—223
10. Risk factors for hypertension and impact of postoperative hypertension on medium survival after heart transplantation.	Page:215—218
11. Efficacy of subgroup mouse bone mesenchymal stem cells on mobilizing autologous cardiac stem cells and repairing ischemic myocardial tissue.	Page:210—214
12. Effects of trimetazidine therapy on left ventricular function after percutaneous coronary intervention.	Page:205—209
13. An initial study on the feasibility of diagnosing myocardial ischemia with CT first-pass myocardial perfusion imaging at rest.	Page:199—204
14. Short-term prognosis and risk factors of ventricular septal rupture following acute myocardial infarction.	Page:195—198
15. Chinese expert recommendation on stroke risk stratification in nonvalvular atrial fibrillation patients.	Page:181—182
16. What have we learned from the expert consensus of antiplatelet therapy in cardiovascular disease?.	Page:179—180